Involvement of opioid mu1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission.
The role of mu1-opioid receptors in the acceleration of cerebral dopaminergic transmission induced by morphine and the putative mu1-opioid agonist, etonitazene, was studied in rats by measuring the tissue levels of dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the dorsal striatum and nucleus accumbens. The striatal extracellular concentrations of DA and its metabolites in freely moving rats were estimated as well. Morphine (3 mg/kg) and etonitazene (2.5 microg/kg) increased the striatal and accumbal dopamine metabolism as measured by the tissue ratios of DOPAC/DA and HVA/DA. The mu1-opioid receptor antagonist, naloxonazine (15 mg/kg), significantly antagonized these elevations except the morphine-induced elevation of striatal HVA/DA ratio. Both morphine (3 mg/kg) and etonitazene (1, 2.5, and 5 microg/kg) elevated the striatal extracellular DA, DOPAC, and HVA. Naloxonazine antagonized the effects of morphine and etonitazene on striatal extracellular DA concentration as well as etonitazene's effects on DOPAC and HVA, but not morphine's effects on DOPAC and HVA. As we previously showed concerning morphine, the conditioned place preference induced by etonitazene was inhibited by naloxonazine. These findings emphasize the role of mu1-opioid receptors in opioid reward, in which the mesolimbic dopaminergic system is considered to be importantly involved. Our results clearly show that in addition to the mesolimbic dopaminergic system the mu1-opioid receptors are also involved in the control of nigrostriatal DA release and metabolism. However, the effects of etonitazene on the striatal DA differ from those of morphine, suggesting that the opioid mechanisms regulating these two DA systems differ.
Piepponen
T P
TP
Department of Pharmacy, University of Helsinki, Finland.
Honkanen
A
A
Kivastik
T
T
Zharkovsky
A
A
Turtia
A
A
Mikkola
J A
JA
Ahtee
L
L
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D003213:Conditioning, Psychological; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D006719:Homovanillic Acid / Q000378:metabolism; D008032:Limbic System / Q000187:drug effects / Q000502:physiology; D008297:Male; D009294:Narcotics / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000187:drug effects* / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology*; D014793:Visual Cortex / Q000187:drug effects / Q000502:physiology
D001562:Benzimidazoles; D009294:Narcotics; D017450:Receptors, Opioid, mu; D015102:3,4-Dihydroxyphenylacetic Acid; C084835:etonitazene; D004298:Dopamine; D006719:Homovanillic Acid